Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease is a genetic disorder with autosomal dominance and variable penetrance, characterized by epistaxis, telangiectasia and visceral manifestations of the disease. The estimated minimal prevalence is 1/10,000 inhabitants. The diagnosis is established on clinical criteria, and may be further confirmed by the identification of causative mutations in either the ENG or the ACVRL1 gene coding for endoglin and ALK1, respectively. Pulmonary vascular manifestations of HHT include pulmonary arteriovenous malforma- tions (PAVMs; especially in patients with ENG mutations) and less frequently pulmonary hypertension (especially in patients with ACVRL1 mutations). In 15–33% of patients with HHT, PAVMs consist of abnormal communications between pulmonary arteries and pulmonary veins, causing right-to-left shunting, and thus, frequently hypoxemia and dyspnea on exertion, although PAVMs may remain asymptomatic and frequently undiagnosed unless complications occur. PAVMs result in severe and frequent complications often at a young age, which may reveal the diagnosis, e.g. transient ischemic attack and cerebral stroke (10–19% of patients), systemic severe infections and abscesses (including cerebral abscess in 5–19% of patients), and rarely massive hemoptysis or hemothorax. Infections in HHT are related to the right-to-left shunting that bypasses the pulmonary capillaries and facilitates the passage of septic or aseptic emboli into the systemic and especially cerebral circulation, and potentially to minor defects in innate immunity. Treatment of PAVMs based on transcatheter coil vaso-occlusion of the feeding artery significantly decreases right-to-left shunting, hypoxemia and dyspnea on exertion, and reduces the risk of systemic complications. Long-term follow-up is warranted after transcatheter vaso-occlusion of PAVMs due to frequent recanalization of treated PAVMs and development or growth of untreated PAVMs. Patients with HHT should be informed of the risk of PAVM and potentially severe complications occurring in heretofore asymptomatic subjects. All adult patients with HHT should be proposed systematic screening for PAVM, by contrast echocardiography (preceded by anteroposterior chest radiograph) or computed tomography of the chest. Pulmonary hypertension is rare in HHT, and may be due either to systemic arteriovenous shunting in the liver increasing cardiac output or be clinically and histologically indistinguishable from idiopathic pulmonary arterial hypertension. Pulmonary hypertension is detected by systematic examination of right cardiac cavities and tricuspid regurgitation flow at echocardiography, and the diagnosis is established by right heart catheterization.

Keywords:
Cerebral abscess, Hereditary hemorrhagic telangiectasia, Pulmonary arteriovenous malformation, Pulmonary hypertension, Rendu-Osler-Weber disease, Right-to-left shunting
1.
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66–67.
2.
Plauchu H, de Chadarevian JP, Bideau A, Robert JM: Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989;32:291–297.
3.
Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabba C: Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 2004;13:1715–1723.
4.
Sabba C, Pasculli G, Suppressa P, D’Ovidio F, Lenato GM, Resta F, Assennato G, Guanti G: Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM 2006;99:327–334.
5.
Babington BG: Hereditary epistaxis. Lancet 1865;ii:362–363.
6.
Legg JW: Royal medical and chirurgical society. Lancet 1876;ii:856–858.
7.
Rendu M: Epistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux. Gaz Hop Paris 1886;135:1322–1326.
8.
Osler W: On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. Bull Johns Hopkins Hosp 1901;128:333–337.
9.
Osler W: On multiple hereditary telangiectases with recurring hemorrhages. QJM 1907;1:53–58.
10.
Weber FP: Multiple hereditary developmental angiomata (telangiectases) of the skin and mucous membranes associated with recurring hemorrhages. Lancet 1907;ii:160–162.
11.
Hanes FM: Multiple hereditary telangiectases causing hemorrhage (hereditary hemorrhagic telangiectasia). Bull Johns Hopkins Hosp 1909;20:63–73.
12.
Cottin V: Clinical genetics for the pulmonologist: introduction. Respiration 2007;74:3–7.
13.
Bideau A, Plauchu H, Brunet G, Robert JM: Etude épidémiologique de la maladie de Rendu-Osler en France: répartition géographique et prévalence. Population 1989;1:9–28.
14.
Guttmacher AE, McKinnon WC, Upton MD: Hereditary hemorrhagic telangiectasia: a disorder in search of the genetics community. Am J Med Genet 1994;52:252–253.
15.
Westermann CJ, Rosina AF, De Vries V, Coteau PA: The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet 2003;116A:324–328.
16.
Begbie ME, Wallace GM, Shovlin CL: Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003;79:18–24.
17.
Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, Gedge F, Tang W, Coon H, Mao R: Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet A 2006;140:463–470.
18.
Cottin V, Chinet T, Lavole A, Corre R, Marchand E, Reynaud-Gaubert M, Plauchu H, Cordier JF: Groupe d’Etudes et de Recherche sur les Maladies ‘Orphelines’ Pulmonaires (GERM’O’P). Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine (Baltimore) 2007;86:1–17.
19.
Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, Watanabe S, Vanwijck R, Vikkula M: Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003;73:1240–1249.
20.
Maniscalco M, Zedda A, Faraone S, de Laurentiis G, Verde R, Molese V, Lapiccirella G, Sofia M: Association of Adams-Oliver syndrome with pulmonary arterio-venous malformation in the same family: a further support to the vascular hypothesis. Am J Med Genet A 2005;136:269–274.
21.
Blanc F, Fleury M, Echaniz-Laguna A, Giraud S, Szwarcberg J, Tranchant C: A rare mimic of hereditary hemorrhagic telangiectasia and conjunctivitis. Ann Intern Med 2007;146:150–151.
22.
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, McCormick MK, Pericak-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJ, Porteous ME, Guttmacher AE, Letarte M, Marchuk DA: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345–351.
23.
Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, Jackson CE, Porteous ME, Marchuk DA: The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997;61:60–67.
24.
Lesca G, Plauchu H, Coulet F, Lefebvre S, Plessis G, Odent S, Riviere S, Leheup B, Goizet C, Carette MF, Cordier JF, Pinson S, Soubrier F, Calender A, Giraud S: Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat 2004;23:289–299.
25.
Pece-Barbara N, Cymerman U, Vera S, Marchuk DA, Letarte M: Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Hum Mol Genet 1999;8:2171–2181.
26.
Gu Y, Jin P, Zhang L, Zhao X, Gao X, Ning Y, Meng A, Chen YG: Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia. Blood 2006;107:1951–1954.
27.
Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M: Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 2001;158:2011–2020.
28.
Bourdeau A, Faughnan ME, Letarte M: Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000;10:279–285.
29.
Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA: A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003;12:473–482.
30.
Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA: A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004;363:852–859.
31.
Wallace GM, Shovlin CL: A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 2000;55:685–690.
32.
Cole SG, Begbie ME, Wallace GM, Shovlin CL: A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005;42:577–582.
33.
Piantanida M, Buscarini E, Dellavecchia C, Minelli A, Rossi A, Buscarini L, Danesino C: Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996;33:441–443.
34.
Porteous ME, Curtis A, Williams O, Marchuk D, Bhattacharya SS, Burn J: Genetic heterogeneity in hereditary haemorrhagic telangiectasia. J Med Genet 1994;31:925–926.
35.
Massagué J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169–178.
36.
Sztrymf B, Yaici A, Girerd B, Humbert M: Genes and pulmonary arterial hypertension. Respiration 2007;74:123–132.
37.
Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC: Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005;111:435–441.
38.
Bhatia S, Morrison JF, Bower TC, McGoon MD: Pulmonary hypertension in the setting of acquired systemic arteriovenous fistulas. Mayo Clin Proc 2003;78:908–912.
39.
Bernard G, Mion F, Henry L, Plauchu H, Paliard P: Hepatic involvement in hereditary hemorrhagic telangiectasia: clinical, radiological, and hemodynamic studies of 11 cases. Gastroenterology 1993;105:482–487.
40.
Trembath RC: Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary haemorrhagic telangiectasia, implies pathway specificity. J Heart Lung Transplant 2001;20:175.
41.
Abdalla SA, Gallione CJ, Barst RJ, Horn EM, Knowles JA, Marchuk D, Letarte M, Morse JH: Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004;23:373–377.
42.
Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Laitinen T, Morrell NW, Trembath RC: Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865–871.
43.
Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, Humbert M: Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59:446–448.
44.
Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, Goizet C, Roume J, Rabilloud M, Saurin JC, Cottin V, Honnorat J, Coulet F, Giraud S, Calender A, Danesino C, Buscarini E, Plauchu H: Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007;9:14–22.
45.
Post MC, Letteboer TG, Mager JJ, Plokker TH, Kelder JC, Westermann CJ: A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005;128:2485–2489.
46.
Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ: Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006;43:371–377.
47.
Heutink P, Haitjema T, Breedveld GJ, Janssen B, Sandkuijl LA, Bontekoe CJ, Westerman CJ, Oostra BA: Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J Med Genet 1994;31:933–936.
48.
McAllister KA, Lennon F, Bowles-Biesecker B, McKinnon WC, Helmbold EA, Markel DS, Jackson CE, Guttmacher AE, Pericak-Vance MA, Marchuk DA: Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J Med Genet 1994;31:927–932.
49.
Berg JN, Guttmacher AE, Marchuk DA, Porteous ME: Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? J Med Genet 1996;33:256–257.
50.
Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T, Lux A, McKinnon W, Marchuk D, Guttmacher A: Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. J Med Genet 2003;40:585–590.
51.
Abdalla SA, Pece-Barbara N, Vera S, Tapia E, Paez E, Bernabeu C, Letarte M: Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2. Hum Mol Genet 2000;9:1227–1237.
52.
Frank NY, Tishler PV: Congenital, metabolic, and neuromuscular diseases; in Silverman EK, Weiss ST, Lomas DA, Shapiro SD (eds): Respiratory genetics. London, Hodder Arnold, 2005, pp 437–457.
53.
Lesca G, Burnichon N, Raux G, Tosi M, Pinson S, Marion MJ, Babin E, Gilbert-Dussardier B, Riviere S, Goizet C, Faivre L, Plauchu H, Frebourg T, Calender A, Giraud S: Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. Hum Mutat 2006;27:598–611.
54.
Schulte C, Geisthoff U, Lux A, Kupka S, Zenner HP, Blin N, Pfister M: High frequency of ENG and ALK1/ACVRL1 mutations in German HHT patients. Hum Mutat 2005;25:595–601.
55.
Abdalla SA, Cymerman U, Rushlow D, Chen N, Stoeber GP, Lemire EG, Letarte M: Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia. Hum Mutat 2005;25:320–321.
56.
Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, Lindhout D, Hennekam FA, Westermann CJ, Ploos van Amstel JK: Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet 2005;116:8–16.
57.
Brusgaard K, Kjeldsen AD, Poulsen L, Moss H, Vase P, Rasmussen K, Kruse TA, Horder M: Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia. Clin Genet 2004;66:556–561.
58.
Gossage JR, Kanj G: Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med 1998;158:643–661.
59.
Remy J, Remy-Jardin M, Giraud F, Wattinne L: Angioarchitecture of pulmonary arteriovenous malformations: clinical utility of three-dimensional helical CT. Radiology 1994;191:657–664.
60.
White RI Jr, Lynch-Nyhan A, Terry P, Buescher PC, Farmlett EJ, Charnas L, Shuman K, Kim W, Kinnison M, Mitchell SE: Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology 1988;169:663–669.
61.
Lee DW, White RI Jr, Egglin TK, Pollak JS, Fayad PB, Wirth JA, Rosenblatt MM, Dickey KW, Burdge CM: Embolotherapy of large pulmonary arteriovenous malformations: long-term results. Ann Thorac Surg 1997;64:930–940.
62.
Dines DE, Arms RA, Bernatz PE, Gomes MR: Pulmonary arteriovenous fistulas. Mayo Clin Proc 1974;49:460–465.
63.
Dutton JA, Jackson JE, Hughes JM, Whyte MK, Peters AM, Ussov W, Allison DJ: Pulmonary arteriovenous malformations: results of treatment with coil embolization in 53 patients. AJR Am J Roentgenol 1995;165:1119–1125.
64.
Gupta P, Mordin C, Curtis J, Hughes JM, Shovlin CL, Jackson JE: Pulmonary arteriovenous malformations: effect of embolization on right-to-left shunt, hypoxemia, and exercise tolerance in 66 patients. AJR Am J Roentgenol 2002;179:347–355.
65.
Swanson KL, Prakash UB, Stanson AW: Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982–1997. Mayo Clin Proc 1999;74:671–680.
66.
Moussouttas M, Fayad P, Rosenblatt M, Hashimoto M, Pollak J, Henderson K, Ma TY, White RI: Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations. Neurology 2000;55:959–964.
67.
Puskas JD, Allen MS, Moncure AC, Wain JC Jr, Hilgenberg AD, Wright C, Grillo HC, Mathisen DJ: Pulmonary arteriovenous malformations: therapeutic options. Ann Thorac Surg 1993;56:253–257, discussion 257–258.
68.
Roman G, Fisher M, Perl DP, Poser CM: Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol 1978;4:130–144.
69.
Haitjema T, Disch F, Overtoom TT, Westermann CJ, Lammers JW: Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995;99:519–524.
70.
Shovlin CL, Letarte M: Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714–729.
71.
Nanthakumar K, Graham AT, Robinson TI, Grande P, Pugash RA, Clarke JA, Hutchison SJ, Mandzia JL, Hyland RH, Faughnan ME: Contrast echocardiography for detection of pulmonary arteriovenous malformations. Am Heart J 2001;141:243–246.
72.
Kjeldsen AD, Oxhoj H, Andersen PE, Green A, Vase P: Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrence of neurological symptoms in patients with hereditary haemorrhagic telangiectasia (HHT). J Intern Med 2000;248:255–262.
73.
Dines DE, Seward JB, Bernatz PE: Pulmonary arteriovenous fistulas. Mayo Clin Proc 1983;58:176–181.
74.
Giordano P, Nigro A, Del Vecchio GC, Sabba C, De Mattia D: HHT in childhood: screening for special patients. Curr Pharm Des 2006;12:1221–1225.
75.
Curie A, Lesca G, Cottin V, Edery P, Bellon G, Faughnan ME: Long-term follow-up in 12 children with pulmonary arteriovenous malformations: confirmation of hereditary hemorrhagic telangiectasia in all cases. J Pediatr, in press.
76.
Haitjema T, Westermann CJ, Overtoom TT, Timmer R, Disch F, Mauser H, Lammers JW: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996;156:714–719.
77.
Whyte MK, Hughes JM, Jackson JE, Peters AM, Hempleman SC, Moore DP, Jones HA: Cardiopulmonary response to exercise in patients with intrapulmonary vascular shunts. J Appl Physiol 1993;75:321–328.
78.
Shovlin CL, Winstock AR, Peters AM, Jackson JE, Hughes JM: Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. QJM 1995;88:879–887.
79.
Ference BA, Shannon TM, White RI Jr, Zawin M, Burdge CM: Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994;106:1387–1390.
80.
Press OW, Ramsey PG: Central nervous system infections associated with hereditary hemorrhagic telangiectasia. Am J Med 1984;77:86–92.
81.
Maher CO, Piepgras DG, Brown RD Jr, Friedman JA, Pollock BE: Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001;32:877–882.
82.
Gallitelli M, Guastamacchia E, Resta F, Guanti G, Sabba C: Pulmonary arteriovenous malformations, hereditary hemorrhagic telangiectasia, and brain abscess. Respiration 2006;73:553–557.
83.
Dupuis-Girod S, Giraud S, Decullier E, Lesca G, Cottin V, Faure F, Merrot O, Saurin JC, Cordier JF, Plauchu H: Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association. Clin Infect Dis 2007;44:841–845.
84.
Engelhardt K, Kampfl A, Spiegel M, Pfausler B, Hausdorfer H, Schmutzhard E: Brain abscess due to Capnocytophaga species, Actinomyces species, and Streptococcus intermedius in a patient with cyanotic congenital heart disease. Eur J Clin Microbiol Infect Dis 2002;21:236–237.
85.
Gallitelli M, Lepore V, Pasculli G, Di Gennaro L, Logroscino G, Carella A, White RI, Sabba C: Brain abscess: a need to screen for pulmonary arteriovenous malformations. Neuroepidemiology 2005;24:76–78.
86.
Sajeev CG, Fasaludeen M, Venugopal K: Pulmonary arteriovenous fistula presenting as brain abscess. Int J Cardiol 2005;98:153.
87.
Emery E, Redondo A, Ouahes O, Berthelot JL, Bouali I, Rey A: Aspects neurochirurgicaux de la maladie de Rendu-Osler. A propos de 6 cas récents et revue de la littérature. Neurochirurgie 1996;42:221–228.
88.
Tattevin P, Bruneel F, Clair B, Lellouche F, de Broucker T, Chevret S, Bedos JP, Wolff M, Regnier B: Bacterial brain abscesses: a retrospective study of 94 patients admitted to an intensive care unit (1980 to 1999). Am J Med 2003;115:143–146.
89.
Blanco P, Schaeverbeke T, Baillet L, Lequen L, Bannwarth B, Dehais J: Télangiectasie hémorragique héréditaire de Rendu-Osler et spondylodiscite bactérienne. Rev Med Interne 1998;19:938–939.
90.
David C, Brasme L, Peruzzi P, Bertault R, Vinsonneau M, Ingrand D: Intramedullary abscess of the spinal cord in a patient with a right-to-left shunt: case report. Clin Infect Dis 1997;24:89–90.
91.
Duval X, Djendli S, Le Moing V, Longuet P, Barry B, Leport C, Vilde JL: Recurrent Staphylococcus aureus extracerebral infections complicating hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber disease). Am J Med 2001;110:671–672.
92.
Hazouard E, Ritz-Quillacq L, Herbreteau D, Legras A, Dequin PF, Ginies G: Maladie de Weber-Rendu-Osler: malformation artério-veineuse pulmonaire avec shunt révélé après 5 méningoencéphalites purulentes. Rev Mal Respir 1999;16:95–97.
93.
Cirulli A, Loria MP, Dambra P, Di Serio F, Ventura MT, Amati L, Jirillo E, Sabba C: Patients with hereditary hemorrhagic telangectasia (HHT) exhibit a deficit of polymorphonuclear cell and monocyte oxidative burst and phagocytosis: a possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des 2006;12:1209–1215.
94.
Amati L, Passeri ME, Resta F, Triggiani V, Jirillo E, Sabba C: Ablation of T-helper 1 cell derived cytokines and of monocyte- derived tumor necrosis factor-alpha in hereditary hemorrhagic telangiectasia: immunological consequences and clinical considerations. Curr Pharm Des 2006;12:1201–1208.
95.
Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF: Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004;169:994–1000.
96.
Anonymous: CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997;349:1641–1649.
97.
Thenganatt J, Schneiderman J, Hyland RH, Edmeads J, Mandzia JL, Faughnan ME: Migraines linked to intrapulmonary right-to-left shunt. Headache 2006;46:439–443.
98.
Post MC, Thijs V, Schonewille WJ, Budts W, Snijder RJ, Plokker HW, Westermann CJ: Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology 2006;66:202–205.
99.
Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J: Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002;13:102–106.
100.
Anzola GP: Clinical impact of patent foramen ovale diagnosis with transcranial Doppler. Eur J Ultrasound 2002;16:11–20.
101.
Remy J, Remy-Jardin M, Wattinne L, Deffontaines C: Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology 1992;182:809–816.
102.
Manson D, Traubici J, Mei-Zahav M, Macluskey I, John P, Stephens D: Pulmonary nodular opacities in children with hereditary hemorrhagic telangiectasia. Pediatr Radiol 2007;37:264–268.
103.
Maillard JO, Cottin V, Etienne-Mastroianni B, Frolet JM, Revel D, Cordier JF: Pulmonary varix mimicking pulmonary arteriovenous malformation in a patient with Turner syndrome. Respiration 2007;74:110–113.
104.
Halbsguth A, Schulze W, Ungeheuer E, Hoer PW: Pitfall in the CT diagnosis of pulmonary arteriovenous malformation. J Comput Assist Tomogr 1983;7:710–712.
105.
Khalil A, Farres MT, Mangiapan G, Tassart M, Bigot JM, Carette MF: Pulmonary arteriovenous malformations. Chest 2000;117:1399–1403.
106.
Berthezene Y, Howarth NR, Revel D: Pulmonary arteriovenous fistula: detection with magnetic resonance angiography. Eur Radiol 1998;8:1403–1404.
107.
Cottin V, Blanchet AS, Cordier JF: Pulmonary manifestations of hereditary hemorrhagic telangiectasia (in French). Rev Mal Respir 2006;23(suppl 2):4S53–4S66.
108.
Barzilai B, Waggoner AD, Spessert C, Picus D, Goodenberger D: Two-dimensional contrast echocardiography in the detection and follow-up of congenital pulmonary arteriovenous malformations. Am J Cardiol 1991;68:1507–1510.
109.
Stewart MJ: Contrast echocardiography. Heart 2003;89:342–348.
110.
Adams HP Jr: Patent foramen ovale: paradoxical embolism and paradoxical data. Mayo Clin Proc 2004;79:15–20.
111.
Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, Gray W, Nakamura M, Mooney M, Poulose A, Schwartz RS: Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol 2005;46:1768–1776.
112.
Zukotynski K, Chan RP, Chow CM, Cohen JH, Faughnan ME: Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest 2007, Epub ahead of print.
113.
Pick A, Deschamps C, Stanson AW: Pulmonary arteriovenous fistula: presentation, diagnosis, and treatment. World J Surg 1999;23:1118–1122.
114.
Lee WL, Graham AF, Pugash RA, Hutchison SJ, Grande P, Hyland RH, Faughnan ME: Contrast echocardiography remains positive after treatment of pulmonary arteriovenous malformations. Chest 2003;123:351–358.
115.
Kjeldsen AD, Oxhoj H, Andersen PE, Elle B, Jacobsen JP, Vase P: Pulmonary arteriovenous malformations: screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia. Chest 1999;116:432–439.
116.
Gossage JR: The role of echocardiography in screening for pulmonary arteriovenous malformations. Chest 2003;123:320–322.
117.
Chilvers ER, Whyte MK, Jackson JE, Allison DJ, Hughes JM: Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left shunt, and arterial oxygenation in patients with pulmonary arteriovenous malformations. Am Rev Respir Dis 1990;142:420–425.
118.
Bialkowski J, Zabal C, Szkutnik M, Montes JA, Kusa J, Zembala M: Percutaneous interventional closure of large pulmonary arteriovenous fistulas with the amplatzer duct occluder. Am J Cardiol 2005;96:127–129.
119.
Berman W Jr, Fripp RR, Raisher BD, Yabek SM: Transcatheter occlusion of large pulmonary arteriovenous fistula. Catheter Cardiovasc Interv 2000;51:220–222.
120.
Apostolopoulou SC, Kelekis NL, Papagiannis J, Hausdorf G, Rammos S: Transcatheter occlusion of a large pulmonary arteriovenous malformation with use of a Cardioseal device. J Vasc Interv Radiol 2001;12:767–769.
121.
Cil B, Canyigit M, Ozkan OS, Pamuk GA, Dogan R: Bilateral multiple pulmonary arteriovenous malformations: endovascular treatment with the Amplatzer Vascular Plug. J Vasc Interv Radiol 2006;17:141–145.
122.
Hinterseer M, Becker A, Barth AS, Kozlik-Feldmann R, Wintersperger BJ, Behr J: Interventional embolization of a giant pulmonary arteriovenous malformation with right-left-shunt associated with hereditary hemorrhagic telangiectasia. Clin Res Cardiol 2006;95:174–178.
123.
Remy-Jardin M, Wattinne L, Remy J: Transcatheter occlusion of pulmonary arterial circulation and collateral supply: failures, incidents, and complications. Radiology 1991;180:699–705.
124.
Brillet PY, Dumont P, Bouaziz N, Duhamel A, Laurent F, Remy J, Remy-Jardin M: Pulmonary arteriovenous malformation treated with embolotherapy: systemic collateral supply at multidetector CT angiography after 2–20-year follow-up. Radiology 2007;242:267–276.
125.
Hartnell GG, Jackson JE, Allison DJ: Coil embolization of pulmonary arteriovenous malformations. Cardiovasc Intervent Radiol 1990;13:347–350.
126.
Yedlicka JW Jr, Bjarnason H, Hunter DW, Castaneda-Zuniga WR, Amplatz K: Persistent pneumothorax following embolization of a pulmonary arteriovenous malformation. J Vasc Interv Radiol 1994;5:887–889.
127.
Andrivet P, Lofaso F, Carette MF, Allegrini J, Adnot S: Haemodynamics and gas exchange before and after coil embolization of pulmonary arteriovenous malformations. Eur Respir J 1995;8:1228–1230.
128.
Haitjema TJ, Overtoom TTC, Westermann CJJ, Lammers JWJ: Embolisation of pulmonary arteriovenous malformations: results and follow up in 32 patients. Thorax 1995;50:719–723.
129.
Remy-Jardin M, Dumont P, Brillet PY, Dupuis P, Duhamel A, Remy J: Pulmonary arteriovenous malformations treated with embolotherapy: helical CT evaluation of long-term effectiveness after 2–21-year follow-up. Radiology 2006;239:576–585.
130.
White RI Jr, Pollak JS: Pulmonary arteriovenous malformations: diagnosis with three-dimensional helical CT – a breakthrough without contrast media. Radiology 1994;191:613–614.
131.
Milic A, Chan RP, Cohen JH, Faughnan ME: Reperfusion of pulmonary arteriovenous malformations after embolotherapy. J Vasc Interv Radiol 2005;16:1675–1683.
132.
Pollak JS, Saluja S, Thabet A, Henderson KJ, Denbow N, White RI Jr: Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol 2006;17:35–44, quiz 45.
133.
Mager JJ, Overtoom TT, Blauw H, Lammers JW, Westermann CJ: Embolotherapy of pulmonary arteriovenous malformations: long-term results in 112 patients. J Vasc Interv Radiol 2004;15:451–456.
134.
Cottin V, Plauchu H, Dupuis-Girod S, Cordier JF: Pulmonary arterio-venous malformations in patients with hereditary hemorrhagic telangiectasia: follow-up and pathophysiological considerations. J Vasc Interv Radiol, in press.
135.
Litzler PY, Douvrin F, Bouchart F, Tabley A, Lemercier E, Baste JM, Redonnet M, Haas-Hubscher C, Clavier E, Bessou JP: Combined endovascular and video-assisted thoracoscopic procedure for treatment of a ruptured pulmonary arteriovenous fistula: case report and review of the literature. J Thorac Cardiovasc Surg 2003;126:1204–1207.
136.
Faughnan ME, Hyland RH, Nanthakumar K, Redelmeier DA: Screening in hereditary hemorrhagic telangiectasia patients. Chest 2000;118:566–567.
137.
Reynaud-Gaubert M, Thomas P, Gaubert JY, Pietri P, Garbe L, Giudicelli R, Orehek J, Fuentes P: Pulmonary arteriovenous malformations: lung transplantation as a therapeutic option. Eur Respir J 1999;14:1425–1428.
138.
Svetliza G, De la Canal A, Beveraggi E, Giacoia A, Ruiz C, Caruso E, Rodriguez Gimenez J, Vassallo B: Lung transplantation in a patient with arteriovenous malformations. J Heart Lung Transplant 2002;21:506–508.
139.
Oxhoj H, Kjeldsen AD, Nielsen G: Screening for pulmonary arteriovenous malformations: contrast echocardiography versus pulse oximetry. Scand Cardiovasc J 2000;34:281–285.
140.
Morrell NW: Screening for pulmonary arteriovenous malformations. Am J Respir Crit Care Med 2004;169:978–979.
141.
Swinburne AJ, Fedullo AJ, Gangemi R, Mijangos JA: Hereditary telangiectasia and multiple pulmonary arteriovenous fistulas. Clinical deterioration during pregnancy. Chest 1986;89:459–460.
142.
Laroche CM, Wells F, Shneerson J: Massive hemothorax due to enlarging arteriovenous fistula in pregnancy. Chest 1992;101:1452–1454.
143.
Hyland RH, Faughnan ME: Pregnancy and post-partum presentations of pulmonary arteriovenous malformations. Eur Respir J 2002;20:26s.
144.
Jakobi P, Weiner Z, Best L, Itskovitz-Eldor J: Hereditary hemorrhagic telangiectasia with pulmonary arteriovenous malformations. Obstet Gynecol 2001;97:813–814.
145.
Gammon RB, Miksa AK, Keller FS: Osler-Weber-Rendu disease and pulmonary arteriovenous fistulas. Deterioration and embolotherapy during pregnancy. Chest 1990;98:1522–1524.
146.
Gershon AS, Faughnan ME, Chon KS, Pugash RA, Clark JA, Bohan MJ, Henderson KJ, Hyland RH, White RI Jr: Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy. Chest 2001;119:470–477.
147.
Mei-Zahav M, Letarte M, Faughnan ME, Abdalla SA, Cymerman U, MacLusky IB: Symptomatic children with hereditary hemorrhagic telangiectasia: a pediatric center experience. Arch Pediatr Adolesc Med 2006;160:596–601.
148.
Faughnan ME, Thabet A, Mei-Zahav M, Colombo M, Maclusky I, Hyland RH, Pugash RA, Chait P, Henderson KJ, White RI Jr: Pulmonary arteriovenous malformations in children: outcomes of transcatheter embolotherapy. J Pediatr 2004;145:826–831.
149.
Folz BJ, Zoll B, Alfke H, Toussaint A, Maier RF, Werner JA: Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents. Eur Arch Otorhinolaryngol 2006;263:53–61.
150.
Reyes-Mujica M, Lopez-Corella E, Perez-Fernandez L, Cuevas-Schacht F, Carrillo-Farga J: Osler-Weber-Rendu disease in an infant. Hum Pathol 1988;19:1243–1246.
151.
Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M, Wheeler L: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325–334.
152.
Varnholt H, Kradin R: Pulmonary capillary hemangiomatosis arising in hereditary hemorrhagic telangiectasia. Hum Pathol 2004;35:266–268.
153.
Clayton T, Banks KP, Bui-Mansfield LT: AJR teaching file: high-output cardiac failure in a patient with a history of hereditary hemorrhagic telangiectasia. AJR Am J Roentgenol 2006;187:S508–S510.
154.
Buscarini E, Plauchu H, Garcia Tsao G, White RI Jr, Sabba C, Miller F, Saurin JC, Pelage JP, Lesca G, Marion MJ, Perna A, Faughnan ME: Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int 2006;26:1040–1046.
155.
Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, Pollak JS, White RI Jr: Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000;343:931–936.
156.
Lerut J, Orlando G, Adam R, Sabba C, Pfitzmann R, Klempnauer J, Belghiti J, Pirenne J, Thevenot T, Hillert C, Brown CM, Gonze D, Karam V, Boillot O: Liver transplantation for hereditary hemorrhagic telangiectasia: Report of The European Liver Transplant Registry. Ann Surg 2006;244:854–862, discussion 862–864.
157.
Boillot O, Bianco F, Viale JP, Mion F, Mechet I, Gille D, Delaye J, Paliard P, Plauchu H: Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology 1999;116:187–192.
158.
Minai OA, Rigelsky C, Eng C, Arroliga AC, Stoller JK: Long-term outcome in a patient with pulmonary hypertension and hereditary hemorrhagic telangiectasia. Chest 2007;131:984–987.
159.
Olivieri C, Lanzarini L, Pagella F, Semino L, Corno S, Valacca C, Plauchu H, Lesca G, Barthelet M, Buscarini E, Danesino C: Echocardiographic screening discloses increased values of pulmonary artery systolic pressure in 9 of 68 unselected patients affected with hereditary hemorrhagic telangiectasia. Genet Med 2006;8:183–190.
160.
Haitjema T, ten Berg JM, Overtoom TTC, Ernst JMPG, Westermann CJJ: Unusual complications after embolization of a pulmonary arteriovenous malformation. Chest 1996;109:1401–1404.
161.
Sapru RP, Hutchinson DCS, Hall JI: Pulmonary hypertension in patients with pulmonary arteriovenous fistulae. Br Heart J 1969;31:559–569.
162.
Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189–195.
163.
Bossler AD, Richards J, George C, Godmilow L, Ganguly A: Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006;27:667–675.
164.
Kjeldsen AD, Moller TR, Brusgaard K, Vase P, Andersen PE: Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Intern Med 2005;258:349–355.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.